Use of a fibrin preparation in the engineering of a vascular graft model

被引:40
作者
Aper, T
Teebken, OE
Steinhoff, G
Haverich, A
机构
[1] Hannover Med Sch, Div Thorac & Cardiovasc Surg, Leibniz Res Labs Biotechnol & Artificial Organs, D-30625 Hannover, Germany
[2] Univ Rostock, Dept Cardiac Surg, Rostock, Germany
关键词
tissue engineering; fibrin; polyglactin; artificial vascular graft; cell seeding; endothelial cell; myofibroblast; in vitro;
D O I
10.1016/j.ejvs.2004.05.016
中图分类号
R61 [外科手术学];
学科分类号
摘要
Objective. Morphological and functional characterization of cocultured endothelial cells (EC) and myofibroblasts (MFB) seeded on a matrix composed of a fibrin preparation mimicking the microenvironment of a vascular wall. Methods. MFB and EC were isolated from human saphenous veins and expanded separately in vitro. MFB were seeded on a composite matrix consisting of a fibrin preparation (with or without transforming growth factor-beta2) and a polyglactin-mesh to form a 3-dimensional structure, which was consecutively reseeded with EC. Seeded matrices were incubated in a bioreactor. Characterization was done including fluorescence staining, live-/dead-assay and immunohistochemistry. Results. High density cocultures in hierarchical structure mimicking the formation of a vascular wall were obtained with nearly complete coverage of the surface with EC. Distribution of preseeded MFB in a 519 +/- 27 mum thick layer (day 14) was achieved. Cell viability was shown in fluorescence staining for at least 19 days. In deeper layers, no viable cells could be detected within the fibrin preparation. EC covered the surface, had uniform morphology, and their preserved viability was shown for at least 5 days. No EC-ingrowth was found into the fibrin preparation. Neoformation of the matrix proteins laminin and collagen IV was observed. Conclusion. A structured coculture of MFB and EC was obtained mimicking the formation of a vascular wall with preserved viability utilizing a fibrin preparation. Nutrition problems seem to limit the maximal extent of MFB in the matrix.
引用
收藏
页码:296 / 302
页数:7
相关论文
共 19 条
  • [1] ELASTICITY OF CANINE AND HUMAN CORONARY-ARTERIES WITH REFERENCE TO POSTMORTEM CHANGES
    GOW, BS
    HADFIELD, CD
    [J]. CIRCULATION RESEARCH, 1979, 45 (05) : 588 - 594
  • [2] Preparation of a pure autologous biodegradable fibrin matrix for tissue engineering
    Haisch, A
    Loch, A
    David, J
    Pruss, A
    Hansen, R
    Sittinger, M
    [J]. MEDICAL & BIOLOGICAL ENGINEERING & COMPUTING, 2000, 38 (06) : 686 - 689
  • [3] HERRING M, 1978, SURGERY, V84, P498
  • [4] α1-Proteinase inhibitor, α1-antichymotrypsin, or α2-macroglobulin is required for vascular smooth muscle cell spreading in three-dimensional fibrin gel
    Ikari, Y
    Fujikawa, K
    Yee, KO
    Schwartz, SM
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (17) : 12799 - 12805
  • [5] Ikari Y, 2000, THROMB HAEMOSTASIS, V84, P701
  • [6] Fibrin gel-advantages of a new scaffold in cardiovascular tissue engineering
    Jockenhoevel, S
    Zund, G
    Hoerstrup, SP
    Chalabi, K
    Sachweh, JS
    Demircan, L
    Messmer, BJ
    Turina, M
    [J]. EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2001, 19 (04) : 424 - 430
  • [7] Tissue engineering: Complete autologous valve conduit - A new moulding technique
    Jockenhoevel, S
    Chalabi, K
    Sachweh, JS
    Groesdonk, HV
    Demircan, L
    Grossmann, M
    Zund, G
    Messmer, BJ
    [J]. THORACIC AND CARDIOVASCULAR SURGEON, 2001, 49 (05) : 287 - 290
  • [8] SELECTIVE STIMULATION OF ENDOTHELIAL-CELL PROLIFERATION WITH INHIBITION OF SMOOTH-MUSCLE CELL-PROLIFERATION BY FIBROBLAST GROWTH-FACTOR-I PLUS HEPARIN DELIVERED FROM FIBRIN GLUE SUSPENSIONS
    KANG, SS
    GOSSELIN, C
    REN, DW
    GREISLER, HP
    [J]. SURGERY, 1995, 118 (02) : 280 - 287
  • [9] TISSUE ENGINEERING
    LANGER, R
    VACANTI, JP
    [J]. SCIENCE, 1993, 260 (5110) : 920 - 926
  • [10] VIABILITY OF HUMAN CORNEAL ENDOTHELIUM FOLLOWING OPTISOL-GS STORAGE
    MEANS, TL
    GEROSKI, DH
    HADLEY, A
    LYNN, MJ
    EDELHAUSER, HF
    [J]. ARCHIVES OF OPHTHALMOLOGY, 1995, 113 (06) : 805 - 809